Shazia Iqbal

New terpenoids from Stachys parviflora Benth

Two new triterpenoidal saponins were isolated from the n‐butanolic extract of Stachys parviflora (Lamiaceae). Their structures were elucidated on the basis of spectral data as stachyssaponin A; 3β, 15α, 19α, 21β, 22α‐pentahydroxyolean‐12‐ene‐28‐oic acid 3‐O‐{α‐L‐rhamnopyranosyl‐(1 → 3)‐β‐D‐glucopyranoside}‐22‐O‐{α‐L‐arabinofuranosyl‐(1 → 3)‐β‐D‐glucopyranoside} (1) and stachyssaponin B; 2β, 3β, 15α, 21β‐tetrahydroxyolean‐12‐ene‐28‐oic acid 2‐O‐[α‐L‐arabinofuranoside]‐3, 21‐bis‐O‐[β‐D‐glucopyranoside] (2). Copyright

New phenethyl alcohol glycosides from Stachys parviflora.

Phytochemical investigations of the whole plant of Stachys parviflora (Lamiaceae) resulted in the isolation of two new phenethyl alcohol glycosides. The structures of the new compounds named parviflorosides A and B were established as 2-(3,4-dihydroxyphenyl)-ethyl-O-α-l-rhamnopyranosyl-(1 → 2)-4-O-E-caffeoyl-β-d-glucopyranoside (1) and 2-(3,4-dihydroxyphenyl)-ethyl-O-α-l-rhamnopyranosyl-(1 → 2)-6-O-E-caffeoyl-β-d-glucopyranoside (2), respectively. The structure elucidation of the new compounds was based primarily on 1D and 2D NMR analysis, including COSY, HMBC and HMQC correlations.

New carbazole linked 1,2,3-triazoles as highly potent non-sugar α-glucosidase inhibitors

In the present study, a series of new carbazole linked 1H-1,2,3-triazoles (2-27) were synthesized via click reaction of N-propargyl-9H-carbazole (1) and azides of appropriate acetophenones and heterocycles. Synthesized carbazole triazoles including 7, 9, 10, 19, 20, and 23-26 (IC50=0.8±0.01-100.8±3.6μM), exhibited several folds more potent α-glucosidase inhibitory in vitro activity as compared to standard drug, acarbose. Compounds 2-5, 7-13, and 17-27 did not show any cytotoxicity against 3T3 cell lines, except triazoles 6, and 14-16. Among the series, carbazole triazoles 23 (IC50=1.0±0.057μM) and 25 (IC50=0.8±0.01μM) were found to be most active, and could serve as an attractive building block in the search of new non-sugar derivatives as anti-diabetic agents.

A new acylated flavone glycoside from the fruits of Stocksia brauhica

Phytochemical investigations of the fruits of Stocksia brauhica (Sapindaceae) resulted in the isolation of a new acylated flavone glycoside. Its structure of the new compound brauhenefloroside D (1) was established as 3-O-[(α-L-rhamnopyranosyl)oxy]-7-O-[(acetyl)-β-D-glucopyranosyl (1 → 4)]-[6-O-(4-hydroxy-E-cinnamoyl)-β-D-glucopyranosyl-(1 → 2)-α-L-rhamnopyranosyl)-oxy]-kaempferol. The structure elucidation of the new compound was based primarily on 1D and 2D NMR analysis, including COSY, HMBC and HMQC correlations.

Brauhenefloroside E and F; acylated flavonol glycosides from Stocksia brauhica Linn

Two new acylated flavonol glycosides, 3‐O‐{[2‐O‐β‐D‐glucopyranosyl]‐3‐[O‐β‐D‐glucopyranosyl]‐4‐[(6‐O‐p‐coumaroyl)‐O‐β‐D‐glucopyranosyl]}‐α‐L‐rhamnopyranosyl‐kaempferol 7‐O‐α‐L‐rhamnopyranoside and 3‐O‐{2‐[(6‐O‐p‐coumaroyl)‐O‐β‐D‐glucopyranosyl]‐3‐[O‐β‐D‐glucopyranosyl]‐4‐[(6‐O‐p‐coumaroyl)‐O‐β‐D‐glucopyranosyl]}‐α‐L‐rhamnopyranosyl‐kaempferol 7‐O‐α‐L‐rhamnopyranoside, trivially named as brauhenefloroside E (1) and F (2), respectively, were isolated from the fruits of Stocksia brauhica and their structures were elucidated using spectroscopic methods, including 2D NMR experiments. Copyright

Isolation of a new lipoxygenase active saponin and a new triterpenoid from the leaves of trachelospermum lucidum

A new saponin trivially named leucioside (1) and a new triterpenoid along with two known lignans trachelosiaside (3) and matairesionol (4) C-glycosides, were isolated from the butanolic fraction of Trachelospermum lucidum. Compounds 1 and 4 showed potent inhibitory activity against lipoxygenase while compounds 2 and 3 showed moderate activity against lipoxygenase.

Specific Determination of Catechol

Abstract The chromogenic reaction of catechol with phloroglucinol is improved by substitution of an alcoholic media for an aqueous one. From 0.05–1.1 ppm of catechol can be assayed, with a standard deviation of ± 0.01.

915 STRATIFICATION OF RISK FACTORS FOR NEPHROPATHY IN HYPERTENSIVE DIABETICS

Objectives: Significant proportion of diabetics develop nephropathy in time and hypertension is considered as an adverse influencing factor.The aim was to identify risk factors related to possible deterioration in renal function among Bangladeshi type 2 diabetic hypertensive (DH) subjects. Method: Diabetic subjects with normal renal function (estimated GFR ≥60 ml/min and urinary albumin <30 mg/day) were included in this cross sectional study. Hypertension was taken as BP ≥140/90mmHg when untreated or taking ≥2 antihypertensives. Results: In DH group 342 and another 496 normotensive diabetic (DM) as control group were included. The comparisons between 2 groups respectively showed systolic BP 130 ± 14 vs. 118 ± 11 and diastolic BP 80 ± 7 vs. 76 ± 6, mmHg; (p < 0.001). The diabetes duration was 8 ± 5 vs. 8 ± 4 yrs, HbA1c 8.1 ± 1.8 vs. 7.1 ± 1.3, %; Serum creatinine (SCr) 0.9 ± 0.1 vs. 0.9 ± 0.2, mg/dl and LDL 103 ± 35 vs. 99 ± 37, mg/dl; (P =NS) were similar. The differences in 2 groups, though mostly clinically less significant, were for age 55 ± 8 vs. 53 ± 8 yrs, (p < 0.001); BMI 25 ± 4 vs. 24 ± 2 kg/m2, (p < 0.03); 24hr urinary albumin (Uralb) 10.9 ± 6.4 vs. 9.6 ± 6.4 mg/day (p < 0.01) and estimated GFR 80 ± 20 vs. 84 ± 21 ml/ming/1.73m2, (p < 0.004). Bivariate correlations showed only age had a negative association with SCr, Uralb and eGFR. Further stratification showed around 65% from both DH and DM groups was in the lower range of eGFR (60-90 ml/min).When DH group was compared for eGFR above and below 90 ml/min (33 vs. 67%), no difference was seen for most of the clinical or laboratory parameters (systolic 129 ± 12 vs. 130 ± 14 & diastolic BP 80 ± 7 vs. 79 ± 7, mmHg; and SCr 0.7 ± 0.1 vs. 0.9 ± 0.1, mg/dl; p = NS) Conclusion: It is found that majority of type 2 diabetics with hypertension had lower normal renal function which could only be identified by estimating GFR. Both groups of high and low renal function had similar traditional clinical and laboratory parameters. Additional tools are needed to stratify which of the hypertensives are more at risk for developing nephropathy.